CYP2D6 and CYP2C19 genotyping in psychiatry: bridging the gap between practice and lab

Anne (Bregje) Koopmans

doi:10.26481/dis.20210512ak

CYP2D6 and CYP2C19 genotyping in psychiatry: bridging the gap between practice and lab

Anne (Bregje) Koopmans

Research output: Thesis › Doctoral Thesis › External prepared

1798 Downloads (Pure)

Abstract

CYP2D6 and CYP2C19 are liver enzymes that play an important role in the breakdown of psychopharmaceuticals. The number of active alleles in the DNA determines how quickly these enzymes work and is translated into a phenotype. This phenotype can vary greatly per person and per ethnicity. There is a relationship between the speed of the enzyme and the occurrence of medication side effects. This study has mapped the prevalence of the different phenotypes worldwide. It has also been investigated whether there are fewer side effects in patients taking antipsychotics if you adjust the dosage of medication to the phenotype.

Original language	English
Awarding Institution	Maastricht University
Supervisors/Advisors	van Harten, Pieter, Supervisor Hoek, H.W., Supervisor, External person Vinkers, D.J., Co-Supervisor, External person
Award date	12 May 2021
Place of Publication	Maastricht
Publisher	ProefschriftMaken
DOIs	https://doi.org/10.26481/dis.20210512ak
Publication status	Published - 2021

Keywords

CYP2D6
CYP2C19
pharmacogenetics
genotyping
clinical practice

Access to Document

10.26481/dis.20210512ak

Full TextFinal published version, 3.19 MB
AbstractFinal published version, 208 KB
PropositionsFinal published version, 93.4 KB
CoverFinal published version, 25.1 KB
ImpactFinal published version, 108 KB

Cite this

@phdthesis{23bc702616f145dba160394778d64eac,

title = "CYP2D6 and CYP2C19 genotyping in psychiatry: bridging the gap between practice and lab",

abstract = "CYP2D6 and CYP2C19 are liver enzymes that play an important role in the breakdown of psychopharmaceuticals. The number of active alleles in the DNA determines how quickly these enzymes work and is translated into a phenotype. This phenotype can vary greatly per person and per ethnicity. There is a relationship between the speed of the enzyme and the occurrence of medication side effects. This study has mapped the prevalence of the different phenotypes worldwide. It has also been investigated whether there are fewer side effects in patients taking antipsychotics if you adjust the dosage of medication to the phenotype.",

keywords = "CYP2D6, CYP2C19, pharmacogenetics, genotyping, clinical practice",

author = "Koopmans, \{Anne (Bregje)\}",

note = "Fout ISBN in proefschrift: 9789077877254 ",

year = "2021",

doi = "10.26481/dis.20210512ak",

language = "English",

publisher = " ProefschriftMaken",

address = "Netherlands",

school = "Maastricht University",

}

TY - BOOK

T1 - CYP2D6 and CYP2C19 genotyping in psychiatry

T2 - bridging the gap between practice and lab

AU - Koopmans, Anne (Bregje)

N1 - Fout ISBN in proefschrift: 9789077877254

PY - 2021

Y1 - 2021

N2 - CYP2D6 and CYP2C19 are liver enzymes that play an important role in the breakdown of psychopharmaceuticals. The number of active alleles in the DNA determines how quickly these enzymes work and is translated into a phenotype. This phenotype can vary greatly per person and per ethnicity. There is a relationship between the speed of the enzyme and the occurrence of medication side effects. This study has mapped the prevalence of the different phenotypes worldwide. It has also been investigated whether there are fewer side effects in patients taking antipsychotics if you adjust the dosage of medication to the phenotype.

AB - CYP2D6 and CYP2C19 are liver enzymes that play an important role in the breakdown of psychopharmaceuticals. The number of active alleles in the DNA determines how quickly these enzymes work and is translated into a phenotype. This phenotype can vary greatly per person and per ethnicity. There is a relationship between the speed of the enzyme and the occurrence of medication side effects. This study has mapped the prevalence of the different phenotypes worldwide. It has also been investigated whether there are fewer side effects in patients taking antipsychotics if you adjust the dosage of medication to the phenotype.

KW - CYP2D6

KW - CYP2C19

KW - pharmacogenetics

KW - genotyping

KW - clinical practice

U2 - 10.26481/dis.20210512ak

DO - 10.26481/dis.20210512ak

M3 - Doctoral Thesis

PB - ProefschriftMaken

CY - Maastricht

ER -

CYP2D6 and CYP2C19 genotyping in psychiatry: bridging the gap between practice and lab

Abstract

Keywords

Access to Document

Fingerprint

Cite this